Execs On The Move, September 2014
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
| Table |
|---|
Advertisement
Topics
- Industries
- BioPharmaceutical
- Medical Device
Related Companies
- Ultragenyx Pharmaceutical Inc.
- Blueprint Medicines Corp.
- Dendreon Corp.
- Avalanche Biotechnologies Inc.
- Paratek Pharmaceuticals Inc.
- Microchips Biotech Inc.
- Signal Genetics Inc.
- Zenith Epigenetics Ltd.
- ConvaTec Group PLC
- Lexicon Pharmaceuticals Inc.
- ImaginAb Inc.
- Acadia Pharmaceuticals Inc.
- Egalet Corp.
- RestorGenex Corp.
- JenaValve Technology GmbH
- Dyadic International Inc.
- Vitae Pharmaceuticals Inc.
- Achaogen Inc.
- Loxo Oncology Inc.
- bioTheranostics Inc.
- Nexstim PLC
- Histogenics Corp.
- HeartWare International Inc.
- Zafgen Inc.
- Loxo Oncology Inc.
- Exosome Diagnostics Inc.
- Aerie Pharmaceuticals Inc.
- Walgreen Co.
- Asuragen Inc.
- Vitae Pharmaceuticals Inc.
- Jounce Therapeutics Inc.
- DNAnexus Inc.
- TesoRx Pharma LLC
- Teva Pharmaceutical Industries Ltd.
- Baxalta Inc.
- Milestone Pharmaceuticals Inc.
- Assertio Therapeutics Inc.
- Neurovance Inc.
- Codexis Inc.
- Signal Genetics Inc.
- Global Blood Therapeutics Inc.
- Exicure Inc.
- Viamet Pharmaceuticals Inc.
- Loxo Oncology Inc.
- Bayer HealthCare Pharmaceuticals AG
- RestorGenex Corp.
- Synta Pharmaceuticals Corp.
- Novartis AG
- Xencor Inc.
- Aegerion Pharmaceuticals Inc.
- Arno Therapeutics Inc.
- Paratek Pharmaceuticals Inc.
- Novartis AG
- Cutera Inc.
- Global Blood Therapeutics Inc.
- ConMed Corp.
- Zogenix Inc.
- Topotarget AS
- Alere Inc.
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IV004268
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
IV004268
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.